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Abstract
Objective—To estimate rates and the patterns of depression treatment among adults with Chronic 
Obstructive Pulmonary Disease (COPD) and depression.
Methods—We used a retrospective, cross-sectional study design, pooling data from 2010 and 
2012 Medical Expenditure Panel Survey (MEPS). The study sample consisted of 527 individuals 
aged 21 years or older, diagnosed with COPD and depression. Depression treatment was grouped 
into 3 categories based on those who received: 1) neither antidepressant nor psychotherapy; 2) 
antidepressants only; and 3) psychotherapy combined with antidepressants (combination therapy). 
We conducted chi-squared tests and multinomial logistic regressions to examine factors 
(demographic, socio-economic characteristics, healthcare access, health status, and personal health 
practices) associated with depression treatment among adults with COPD and depression.
Key Findings—The mean age of the study sample was 55.96 years(SD=13.36). Overall, 18.8% 
of the sample adults did not report any use of antidepressants or psychotherapy, 58.3% reported 
antidepressants use only and 23% reported using combination therapy. Females(AOR=1.89, 95% 
CI= 1.02, 3.55), older adults(>=65 years: AOR=3.69, 95% CI= 1.62, 8.41), adults with fair/poor 
physical health status(AOR=3.32, 95% CI=1.29, 8.56) and those suffering from anxiety 
(AOR=1.94, 95% CI= 1.09, 3.46) were more likely to receive antidepressant treatment. Older 
adults(AOR=2.94, 95% CI=1.05, 8.22), those who were never married(AOR=3.17, 95% CI=1.18, 
8.56), suffered from anxiety(AOR=6.01, 95% CI=3.11, 11.61) and current smokers (AOR=2.29, 
95% CI= 1.05, 4.98) were more likely to receive combination therapy. Whereas, adults who were 
uninsured(AOR=0.21, 95% CI= 0.05, 0.86) and did not have physical activity (AOR=0.33, 95% 
CI= 0.16, 0.67) were less likely to receive combination therapy. Key limitations of our study is that 
we could not control for the severity of depression or COPD which may have influenced 
depression treatment.
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Conclusion—Efforts to improve depression care among adults with co-occurring COPD and 
depression may need to be tailored for different subgroups.
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Introduction
Depression is a frequently occurring concomitant disease among adults with Chronic 
Obstructive Pulmonary Disease (COPD) with an estimated prevalence of 24.6%1. Adults 
with COPD are 4 times as likely as those without COPD to develop depression2; and twice 
as likely to develop depression as adults with other chronic conditions such as arthritis, 
cancer, diabetes, hypertension, and stroke3. Depression leads to worsening of COPD-related 
outcomes such as COPD-exacerbation frequency4, 5, symptom burden and COPD treatment 
failure6. Depression also increases severity of COPD due to its effect on early addictive 
smoking and impediment of smoking cessation7. In addition, non COPD-related outcomes 
of depression include longer hospitalization8, mortality9, impaired functional status, poor 
exercise capacity8, poor quality of life10, non-adherence to medical treatment, and sleep 
disturbances8.
Randomized clinical trials (RCTs) have demonstrated the beneficial effect of antidepressants 
use among patients with COPD and depression11. In addition to reduction of depressive 
symptoms, antidepressants may confer other benefits such as decrease in tobacco cravings, 
improvement of subjective dyspnea, improvement of appetite, weight loss reversal, decrease 
in anxiety symptoms and better decision making regarding end-of-life-care preferences12. 
Adding psychotherapy to antidepressant treatment (combination therapy) is also an effective 
strategy in managing depression. Evidence-based clinical practice guidelines 13–15 on the 
management of depression in general population have recommended combined therapy 
(psychotherapy and antidepressant medication) for patients with moderate-to-severe 
depression. In a recent meta-analysis, researchers showed that adding psychotherapy to 
antidepressant medications was twice as effective as compared to antidepressant treatment 
alone 16 in reducing depressive symptoms. However, evidence regarding combination 
therapy use in the management of depression in COPD population has been limited17.
Despite, the high prevalence of depression in patients with COPD and the beneficial effect 
of depression treatment, nationally representative studies on the rates of depression 
treatment in real-world settings among adults with COPD and depression have been 
limited 2, 18. One study conducted in the United States (US) in 2003 reported that only 31% 
of adults with COPD and depression seen in one primary care setting received treatment for 
depression2. Another study using claims data of elderly (>=65 years) Medicare beneficiaries 
found that 82.1% of the elderly COPD patients with depression received antidepressants18. It 
has to be noted that this study focused only on elderly Medicare beneficiaries. Thus, the 
extant literature provides no information on depression treatment in adults with COPD and 
little is known about the various person-level factors that are associated with depression 
treatment in adults with COPD and depression. Therefore, the primary objective of this 
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study was to estimate the rates of depression treatment with antidepressants and combination 
therapy among adults with co-occurring depression and COPD. We also examined the 
patterns of depression treatment by demographic, socio-economic characteristics, access to 
care, health status, and personal health care practices in a nationally representative sample of 
adults with COPD and depression.
Methods
Design
A retrospective cross-sectional study design was used.
Data
We used data from the Medical Expenditure Panel Survey (MEPS), a large-scale survey of 
the civilian non-institutionalized population in the U.S. The Household Component (HC) of 
MEPS collects demographic characteristics, medical conditions, health status, utilization of 
healthcare services, charges and payments, access to care, health insurance coverage, 
income, education and employment on all household members19. For this study we used the 
person-level household full year consolidated file, event-level medical conditions and 
prescribed medicines file. Medical conditions file captures medical conditions of the 
respondents based on the verbatim text and these texts are converted into International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes by 
professional coders 20. The event-level prescribed medications file contains detailed records 
of prescribed medicines such as the national drug code (NDC), medicine name, therapeutic 
class based on Multum Lexicon classification, sources of payment, fill date and others.
MEPS uses a probability weighted complex multistage survey design with primary sampling 
units, strata, and person level sampling weights21. For the current study, we pooled data 
from two years (2010 and 2012) to have sufficient sample size and alternate years were used 
to avoid using two observations per individual.
Study Sample
The study sample comprised of individuals aged 21 years or older, who were diagnosed with 
depression and COPD and were alive during the calendar years. Depression was identified 
using ICD-9-CM codes (296.XX, 298.XX, 300.XX, 309.XX and 311.XX) used in published 
literature and the National Committee on Quality Assurance 22, 23. COPD was identified 
using previously validated ICD-9-CM codes (491.XX, 492.XX and 496.XX) 24, 25.
Measures
All variables (dependent and independent) used in this analysis were identified from the 
same calendar year.
Dependent Variable
Antidepressant Treatment—Information on antidepressant prescriptions was derived 
from Prescribed Medicine file in MEPS using the therapeutic class codes from the Multum-
lexicon classification scheme. The therapeutic class code 249 represented antidepressants. In 
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our study, we considered individuals to have received antidepressant treatment if they had 
one or more prescriptions for antidepressants.
Psychotherapy—Information on Psychotherapy was obtained from the office-based 
medical provider visit files and the outpatient files. These files capture information on the 
reason for visits. In our study, we considered individuals to have received psychotherapy if 
they had at least one visit in which they received psychotherapy.
Based on the receipt of antidepressants and psychotherapy, adults were classified into three 
mutually exclusive depression treatment categories: 1) received neither antidepressants nor 
psychotherapy; 2) received antidepressants only; and 3) received psychotherapy combined 
with antidepressants (combination therapy). As less than 4% (n=23) of the study population 
reported psychotherapy use only, we excluded individuals receiving “psychotherapy only” 
from our population.
Independent Variables
Demographic variables included sex, race (white, African American, other racial minorities), 
age in years (21–39 years, 40–49 years, 50–64 years, 65 and older), marital status (married, 
widowed, separated/divorced, never married), and metro status (metro, rural). Socio-
economic characteristics included education (less than high school, high school, above high 
school) and poverty status (not poor, poor). Access to care variables consisted of health 
insurance (public, private, uninsured) and usual source of care (yes/no). The usual source of 
care variable was based on whether each individual ascertains if there is a particular doctor’s 
office, clinic, health center, or other place from where an individual usually seek care19. 
Health status variables included a diagnosis of anxiety (yes/no), number of chronic 
conditions other than COPD (none, 1 to 3, >3 conditions) from a list of 12 conditions that 
included arthritis, asthma, cancer, dementia, diabetes, heart disease, gastroesophageal reflux 
disease (GERD), hypertension, liver disease, renal disease, stroke, and thyroid disorders, and 
perceived physical health status (excellent/very good, good, and fair/poor). Perceived mental 
health status (excellent/very good, good, and fair/poor) was used as a proxy for the severity 
of depression. Personal health practice variables included Body Mass Index (BMI) 
categories (underweight/normal, overweight, obese), smoking status (current smoker, other) 
and physical activity (moderate to vigorous activities 3 times per week, no physical activity).
Statistical Analysis
Chi-square tests were used to analyze the differences in depression treatment among various 
subgroups of individuals with COPD and depression. Multinomial logistic regressions were 
employed to analyze the depression treatment patterns by gender, age race, marital status, 
metro status, insurance status, usual source of care, medical conditions and health status 
variables. We used “neither antidepressants nor psychotherapy” as the reference group for 
the dependent variable in the multinomial regression model. There were a few individuals 
with missing data (n =24) on BMI and smoking and these individuals were excluded from 
the multinomial logistic regression. Parameter estimates from the multinomial logistic 
regression were transformed into adjusted odds ratio (AOR) and their corresponding 95% 
confidence intervals were reported. To account for the complex, probabilistic survey design 
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of MEPS, all statistics were weighted to the national level by incorporating MEPS variance 
adjustment weights (sampling strata and primary sampling unit) and MEPS person-level 
weights in all analyses. SAS 9.4 (SAS Institute Inc., Cary, NC) software was used to adjust 
the estimated standard errors for weighted survey estimates using the Taylor-series 
linearization approach. This was done by using survey procedures found in SAS such as 
SURVEYFREQ, SURVEYMEANS and SURVEYLOGISTIC.
Results
The sample description of our study population is presented in Table 1. Our study population 
consisted of 527 adults with co-occurring COPD and depression. About 70% were females 
and 82.2% were whites. 45.1% of the study population was in the age group 50–64 years. 
An overwhelming majority of the population (58.7%) reported the presence of 1 to 3 chronic 
illnesses such as arthritis, diabetes mellitus, heart diseases, stroke, hypertension and thyroid 
disorders; nearly 38.4% reported anxiety. In addition, almost 46% of the study population 
was obese and about 40.8% was current smokers.
The un-weighted number and weighted percent of depression treatment categories by socio-
demographic, medical conditions and health status are presented in Table 2. We found that 
18.8% of the study population received neither antidepressants nor psychotherapy, 58.3% 
reported antidepressants use only and 23% reported the use of combination therapy (Table 
2). We observed statistically significant differences in depression treatment by race, age, 
marital status, education, health insurance, usual source of care, perceived mental health 
status, anxiety, current smoking status and number of chronic conditions. A significantly 
higher proportion of racial minorities (other than African Americans) (28.1%) compared to 
whites (15.9%) did not receive any treatment with antidepressants or psychotherapy. Also 
higher proportions of uninsured adults (38.7%) as compared to those with private (14.3%) or 
public insurance (13.8%) did not report any treatment with antidepressants or 
psychotherapy.
Adjusted odds ratios (AOR) and 95% CIs from multinomial logistic regression analysis 
based on depression treatment of the various subgroups are presented in Table 3. Females 
(AOR=1.89, 95% CI= 1.02, 3.55), older adults (>=65 years: AOR=3.69, 95% CI= 1.62, 
8.41), adults with fair/poor physical health status (AOR=3.32, 95% CI=1.29, 8.56) and those 
suffering from anxiety (AOR=1.94, 95% CI= 1.09, 3.46) were more likely to receive 
antidepressant treatment compared to males, younger adults aged 22 to 39 years, adults with 
very excellent/very good physical health status and those who did not suffer from anxiety 
respectively. In contrast, adults with fair/poor mental health status (AOR=0.36, 95% 
CI=0.18, 0.75) as compared to adults with excellent/ very good mental health status were 
less likely to receive antidepressant treatment. Older adults (AOR=2.94, 95% CI=1.05, 
8.22), those who were never married (AOR=3.17, 95% CI=1.18, 8.56), suffered from 
anxiety (AOR=6.01, 95% CI=3.11, 11.61) and current smokers (AOR=2.29, 95% CI= 1.05, 
4.98) were more likely to receive combination therapy compared to younger adults aged 22 
to 39 years, those who were married, did not have anxiety and were not current smokers 
respectively. Whereas, adults who were uninsured (AOR=0.21, 95% CI= 0.05, 0.86) and did 
not have physical activity (AOR=0.33, 95% CI= 0.16, 0.67) were less likely to receive with 
Deb and Sambamoorthi Page 5













the combination therapy as compared to those who had private insurance and had regular 
physical activity respectively.
Discussion
Our study analyzed the rates and patterns of depression treatment among adults with co-
occurring COPD and depression using data from the nationally representative household 
survey, MEPS. The results from our study show that 81.5% of the population with COPD 
and depression received treatment for depression with either antidepressants or combination 
therapy. There are no studies on depression treatment among all adults with COPD and 
depression in the US. Therefore, we compared the rate of antidepressants use among older 
adults (i.e. age ≥ 65 years) in our study to one published study on antidepressant treatment 
among Medicare beneficiaries with COPD and depression18. The percentage of 
antidepressants use in our study (86%) is consistent with Qian et al., which showed that 82% 
of older Medicare beneficiaries with both COPD and depression received treatment with 
antidepressants. However, another study by Kunik et al. reported that only 31% of the 
patients in one primary care center with co-occurring chronic breathing disorders and 
depression received treatment for depression2. Because this study was more than a decade 
old, the difference in the rate of depression treatment may be in part due to study settings, 
single site, changes in practice patterns over time and increasing trends in detection and 
management of depression in outpatient setting26.
We found that more than two-thirds (70%) of adults with co-occurring COPD and 
depression were women. It is well-established that that women are more likely to have 
depression than men across numerous chronic conditions27, 28. Among patients with COPD, 
epidemiologic studies have reported higher prevalence of depression among women than 
men29. Although historically COPD has been considered to affect men disproportionately30, 
in the past decade there has been a shift in the trend of COPD from a male predominant 
disease to a female predominant disease31, 32.Therefore, it is not surprising that an 
overwhelming majority of our study sample were women.
Our results also indicate that women with COPD and depression were significantly more 
likely to receive antidepressant treatment as compared to men. The sex-related disparity in 
depression treatment has been attributed to the lowered willingness of men to seek treatment 
for mental disorders 33–36. In a landmark multisite trial (IMPACT) conducted among older 
adults with depression, qualitative assessments showed that the sex-related disparities in 
depression treatment could be attributed to the stereotypical masculine ideologies such as 
emotional control, self-reliance and stoicism as well as high social stigma associated with 
seeking healthcare for chronic mental disorders33.
We also found that adults with co-occurring COPD and depression who had fair/poor 
physical health status were more likely to receive depression treatment as compared to adults 
with excellent/very good physical health status. A possible explanation for the high 
antidepressant use could be the effectiveness of antidepressants in the alleviation of COPD 
related symptoms such as decrease in exacerbation frequency, dyspnea and COPD related 
treatment failure 4, 5, 11.
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Conversely, adults with fair/poor mental health status were less likely to receive depression 
treatment than adults with excellent/ very good mental health status. In a feasibility trial of 
antidepressant therapy in patients with COPD, it was found that the majority (72%) of 
depressed patients refused antidepressant therapy due to anticipation of adverse events, 
resentment in taking multiple medications, and denial of depressive symptoms37. This might 
explain the reason for low antidepressant use among adults with more severe mental health. 
Future studies need to explore the barriers to antidepressant use among this subpopulation.
Adults with anxiety were 1.9 times as likely to receive antidepressant treatment and 6 times 
as likely to receive combination therapy as compared to those without anxiety. Previous 
research have demonstrated that anxiety among patients with COPD and depression leads to 
significant increase in behavioral and psychological symptoms of distress such as higher 
levels of fatigue, shortness of breath, and frequency of COPD symptoms38. One plausible 
reason for the higher likelihood of combination therapy among adults with COPD and 
depression may be due to the effectiveness of combination therapy in treating a wide variety 
of anxiety symptoms39.
One noteworthy finding from this study is that current smokers were 2.3 times as likely to 
receive combination therapy as compared to those who were not current smokers. Prior 
research has shown that among adults with COPD and depression, who also smoke, have a 
nearly 40-fold increase in risk of severity from COPD interaction effects 7, 9. It is well-
documented that treatment for depression may have the added benefit of facilitating smoking 
cessation in addition to reducing depressive symptoms 40–42 among adults with COPD and 
depression. These findings suggest that current smokers may be treated with combination 
therapy to provide relief from depression as well as smoking cessation.
Despite the effectiveness of combination therapy in providing relief from depression, only 
23% of adults with COPD and depression received combination therapy. Furthermore, 
certain subgroups were less likely to receive combination therapy. For example, we found 
that patients who lacked regular physical activity were less likely to receive combination 
therapy. Exercise is particularly challenging in patients with COPD due to alterations in their 
skeletal muscle caused by their illness 43. In our study, approximately 3 in 4 patients with 
COPD and depression reported lack of exercise perhaps due to exercise intolerance in this 
population. Therefore, physicians may need to pay particular attention to these patients in 
making a decision about the modality of depression treatment.
Our study findings also highlighted lack of health insurance as a barrier to receipt of 
combination therapy. Uninsured may not receive combination therapy due to high out-of-
pocket spending burden. A study of financial burden and out-of-pocket expenditures for 
mental health reported that uninsured adults were more likely to bear a significant burden as 
compared to insured adults 44. This finding suggest a need for clinical practice and policy 
efforts to be integrated. For example, clinicians can attempt to reduce access barriers to 
combination therapy by providing linkages of the various behavioral and social services that 
are available in the community for the underserved or the uninsured45.
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Conversely, results from our study also indicate that certain subgroups of adults - those who 
were older (>=65 years), never married, current smokers and who had anxiety - were more 
likely to receive combination therapy. Our study did not examine the reasons behind the 
higher rates of combination therapy in these groups. Therefore, future studies are needed to 
explore the motivational determinants of combination therapy in these patient subgroups.
The findings of this study are subject to certain limitations. As data from MEPS are self-
reported, it is subject to recall bias. Also, due to the cross-sectional nature of the study, 
causal relationship between depression treatment and other variables cannot be established. 
Furthermore, due to the absence of disease specific severity measure in MEPS, the severity 
of COPD or depression could not be taken into account. In addition, we did not analyze the 
use of alternative and complementary therapies of depression in this population.
Conclusion
Notwithstanding the limitations, our study findings identified subgroups of patients with 
COPD and depression who may be vulnerable for non-receipt of effective depression 
treatment modality (i.e. combination therapy). In our study some subgroups of patients were 
more likely to receive combination therapy, suggesting that these subgroups may have 
accepted combination therapy. Future research needs to explore whether other factors such 
as patient preferences, attitudes, knowledge and willingness to accept combination therapy 
that were not measured in our study contributed to the high rates of combination therapy in 
these groups.
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Table 1
Descriptive Statistics of Study Sample (N=527)
Adults with COPD and Depression;
Medical Expenditure Panel Survey, 2010 and 2012
Variable N Weighted %
All 527 100.0
Sex
 Female 376 69.9
 Male 151 30.1
Race
 White 368 82.2
 African American 71 7.1
 Other 88 10.7
Age in years
 22–39 years 60 11.6
 40–49 years 82 15.5
 50–64 years 243 45.1
 65 and older 142 27.8
Marital Status
 Married 226 44.4
 Widow 69 12.6
 Separated/Divorced 144 25.9
 Never married 88 17.2
Metro
 Metro 423 79.6
 Rural 104 20.4
Education
 Less than High School 127 20.0
 High School 125 20.6
 More than High School 168 39.1
Employment Status
 Employed 135 29.4
 Not Employed 392 70.6
Poverty Status
 Poor 287 46.3
 Not Poor 240 53.7
Insurance Status
 Private 211 48.9
 Public 261 41.8
 Uninsured 55 9.3
Usual Source of Care
 Yes 475 90.7
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Variable N Weighted %
 No 51 9.3
Perceived Physical Health Status
 Excellent/very good 82 18.2
 Good 145 29.6
 Fair/poor 300 52.2
Perceived Mental Health Status
 Excellent/very good 122 24.9
 Good 185 36.1
 Fair/poor 220 39.0
Anxiety
 Yes 192 38.4
 No 335 61.6
Body Mass Index
 Underweight/normal 121 23.7
 Overweight 142 29.4
 Obese 260 45.9
Smoking Status
 Current smoker 227 40.8
 Other 280 55.6
Physical Activity
 3 times per week 133 26.5
 No exercise 394 73.5
Number of Chronic Conditions
 None 52 12.3
 1–3 311 58.7
 4 or more 164 29.1
Note: Based on 527 adults, aged 21 years older with self-reported Chronic Obstructive Pulmonary Disease and depression who were alive during 
the calendar years. Missing categories for education, usual source of care, smoking status, body mass index and physical activity are not displayed.
COPD: Chronic Obstructive Pulmonary Disease
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